骨髓增生异常综合征患者循环microRNA-144的检测及其临床意义

Expression and clinical significance of serum circulating micro RNA-144 in patients with myelodysplastic syndromes

目的探讨mi RNA-144在骨髓增生异常综合征(MDS)患者外周血中的表达情况及其临床意义。方法收集MDS患者24例,健康对照12例,q RT-PCR检测外周血mi RNA-144相对表达量,统计分析mi RNA-144在MDS中的表达情况及与其预后相关性。结果 mi RNA-144在MDS亚型难治性血细胞减少伴单系病态造血(RCUD)、难治性血细胞减少伴多系病态造血(RCMD)、难治性贫血伴环形铁粒幼细胞(RARS)、难治性贫血伴原始细胞增多-1(RAEB-1)及难治性贫血伴原始细胞增多-2(RAEB-2)中的相对表达量分别为3.81、3.64、4.56、6.49及8.73,均显著高于健康对照组,P<0.01;mi RNA-144在预后好和预后差组中的相对表达量分别为3.81和7.18,差异具有统计学意义,P<0.01。结论 mi RNA-144在MDS中高表达,且可作为潜在的预后评估指标。

Objective To investigate the expression and clinical significance of serum circulating mi RNA-144 in the patients with myelodysplastic syndromes. Methods The mi RNA-144 expression levels were detected by q RT-PCR method in 24 MDS patients and 12 health controls. The relationship between mi RNA-144 expression level and MDS prognosis was analyzed. Results The relative expression quantity of mi RNA-144 in MDS subtype RCUD, RCMD, RARS, RAEB-1 and RAEB-2 was 3.81, 3.64,4.56, 6.49 and 8.73 respectively, and significantly higher than that of healthy controls（P〈0.01）. In good survival group and poor survival group, the relative expression quantity of mi RNA-144 was 3.81 and 7.18 respectively, and the difference was statistically significant（P〈0.01）. Conclusion mi RNA-144 is highly expressed in MDS, and may be a new biomarker for prognosis evaluation of MDS.